Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283634 · ClinicalTrials.gov registry record · Phase 2
A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Millennium Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00283634: Clinical Trial Phase 2 study, sponsored by Millennium Pharmaceuticals.
NCT00283634 is a Phase 2 study that was terminated before completion, run by Millennium Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00283634, a Phase 2 study, was terminated before completion, sponsored by Millennium Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
Tarceva, an orally available small molecule, has demonstrated potent activity in tumor models and humans. This randomized, open-label phase 2 study of Tarceva alone and of Tarceva plus VELCADE is designed primarily to determine the objective tumor response rates to these treatments in patients with Stage IIIB or Stage IV non-small cell lung cancer (NSCLC) that is refractory to or has relapsed after front-line chemotherapy.
Interventions
- DRUG erlotinib and bortezomib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-08 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Why NCT00283634 stopped before completion
NCT00283634 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which erlotinib and bortezomib is the first listed.
NCT00283634 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00283634 about?
NCT00283634 is a clinical study titled "A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer". Tarceva, an orally available small molecule, has demonstrated potent activity in tumor models and humans. This randomized, open-label phase 2 study of Tarceva alone and of Tarceva plus VELCADE is designed primarily to determine the objective tumor response rates to these treatments in patients with ...
What is the current status of trial NCT00283634?
This trial is currently terminated. It is a Phase 2 study. The study started on 2005-08. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00283634?
The interventions under investigation include: erlotinib and bortezomib (DRUG).
Who is sponsoring clinical trial NCT00283634?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia